Artificial Intelligence In Genomics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 1.6 billion
Estimated Base Value
2035 Forecast
US$ 12.0 billion
Projected Market Value
CAGR 2026–2035
22.3%
Compound Annual Growth
Largest Segment
AI Software Platforms
Fastest Growing Segment
AI Solutions
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
38.0% market share
Key Players
Tempus Labs
Emerging Players
Insilico Medicine, Valo Health
Market Definition & Overview
The Artificial Intelligence in Genomics Market within the pharmaceutical industry encompasses the application of AI and machine learning algorithms to analyze, interpret, and leverage vast genomic datasets for accelerating drug discovery, development, and personalized medicine. This market focuses on solutions that enhance target identification, lead optimization, biomarker discovery, patient stratification, and adverse drug reaction prediction by processing DNA, RNA, and proteomic information at scale. It aims to improve therapeutic efficacy, optimize clinical trial design, and personalize treatments, ultimately transforming pharmaceutical research and development pipelines and clinical practice.
Scope
- Global market coverage across all major regions
- Analysis by AI technology (e.g., machine learning, deep learning) and genomic application
- Coverage of solutions primarily used by pharmaceutical companies and biotechnology firms
- Historical data and future forecasts spanning typical study periods
Inclusions
- AI-powered software platforms for genomic data analysis and interpretation
- Machine learning algorithms specifically for genetic variant interpretation
- AI tools for drug target identification and validation using genomic data
- AI solutions for precision oncology and pharmacogenomics applications
- Services for AI-driven biomarker discovery and development
- Integration of AI with next-generation sequencing data analysis
Exclusions
- General AI applications not specifically focused on genomics
- Genomic sequencing services without AI integration or analysis
- AI applications in other non-genomic pharmaceutical areas like clinical operations
- Traditional bioinformatics tools lacking advanced AI capabilities
- AI in genomics for non-pharmaceutical sectors like agriculture or consumer genetics
Market Size Forecast
Executive Summary
• The Artificial Intelligence In Genomics market is valued at $1.6 Bn in 2025 and is forecast to reach $12.0 Bn by 2035, reflecting a robust CAGR of 22.3% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 33.0%, while Emerging Areas is expanding the fastest at a 10.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 38.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic alliances and targeted M&A are rapidly reshaping the competitive landscape, with major pharmaceutical companies acquiring AI genomic startups to integrate advanced drug discovery platforms and accelerate therapeutic development pipelines for precision medicine.
• The convergence of declining sequencing costs and advanced AI algorithms is a primary catalyst, propelling the market towards widespread adoption in clinical diagnostics and personalized oncology, profoundly transforming patient stratification and treatment efficacy.
• Breakthroughs in deep learning for genomic variant interpretation and multi-omics integration are pivotal, unlocking unprecedented efficiencies in target identification and lead optimization, significantly compressing drug development timelines across therapeutic areas.
• Evolving regulatory frameworks for AI-driven diagnostics and data governance will critically influence market expansion, demanding robust validation protocols and ethical data-sharing models to foster trust and accelerate clinical integration.
• North America and Europe currently dominate investment and innovation, yet emerging Asian markets with vast, diverse genomic datasets represent significant untapped potential, poised for rapid growth as infrastructure and expertise mature.
• Talent scarcity in bioinformatics and AI engineering remains a critical bottleneck, necessitating strategic investments in workforce development and academic partnerships to sustain innovation and scale market-wide adoption effectively.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Artificial Intelligence in Genomics Market was valued at $1.6 billion in the base year.
Future Market Projection
The market is projected to reach $12.0 billion by the forecast year, indicating substantial expansion.
Robust Growth Outlook
This significant market expansion is driven by an impressive Compound Annual Growth Rate (CAGR) of 22.3%.
Drug Discovery Dominance
The drug discovery and development segment is expected to remain a leading application, leveraging AI for accelerated therapeutic innovation.
Precision Medicine Trend
A notable trend is the increasing adoption of AI for precision medicine, enabling tailored treatments based on individual genetic profiles.
Regional Leadership
North America is anticipated to maintain its leadership position, driven by extensive R&D investments and advanced technological infrastructure.
Market Dynamics
Market Trends
- Increased adoption of AI for genomic data analysis in drug discovery.
- Growing use of machine learning in personalized medicine workflows.
- Integration of multi-omics data with AI for comprehensive insights.
- Rising focus on ethical AI and data privacy in genomic research.
Growth Drivers
- Surge in genomic data generation fuels demand for AI tools.
- Need for accelerated drug discovery and development processes.
- Advances in AI algorithms and computational power.
- Increasing investment from pharmaceutical companies in AI genomics.
Restraints
- Data privacy and security concerns remain a significant hurdle.
- High computational costs limit accessibility for smaller entities.
- Lack of standardized genomic data hinders AI model development.
- Regulatory complexities and ethical considerations pose challenges.
Opportunities
- Development of novel AI solutions for rare disease diagnosis.
- Expansion into pharmacogenomics for tailored drug prescriptions.
- Creating AI platforms for predictive analytics in disease prevention.
- Partnerships between tech firms and genomic research institutions.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI ServicesAI Solutions |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionPredictive AnalyticsReinforcement LearningGenerative AI |
| By Application | Drug Discovery & DevelopmentPrecision MedicineDisease Diagnosis & PrognosisBiomarker DiscoveryGenomic Sequencing & AnnotationVariant PrioritizationClinical TrialsPersonalized Therapeutics |
| By End-User | Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutionsClinical LaboratoriesHospitals & Healthcare ProvidersContract Research OrganizationsGovernment Agencies |
| By Deployment | Cloud-BasedOn-PremiseHybrid |
| By Component | Algorithms & ModelsData Integration & Management ToolsGenomic Databases & Knowledge BasesCloud & Computing InfrastructureVisualization & Reporting ToolsApplication Programming Interfaces & Software Development Kits |
Regional Analysis
- North America leads the AI in genomics market due to its robust R&D infrastructure, substantial venture capital investments, and the presence of key pharmaceutical and biotechnology firms. Extensive government funding and advanced healthcare systems further drive innovation and adoption in this region.
- The Asia Pacific region is rapidly expanding in AI genomics, driven by burgeoning healthcare expenditure, massive patient populations for genomic data, and supportive government policies. Increasing awareness and investment in precision medicine further accelerate its growth across key countries.
- Europe exhibits a noteworthy trend towards collaborative, cross-border genomics projects, leveraging AI for shared data analysis while navigating stringent data privacy regulations (GDPR). This fosters innovation in personalized medicine through multi-national research initiatives.
| Asia Pacific33.0% | North America30.0% | Europe22.0% | Latin America7.0% | Middle East & Africa5.0% | Emerging Areas3.0% |
North America
8.0% CAGR
$480.0 Mn
30% share
- Leading in AI innovation and genomic research, North America benefits from strong venture capital funding, a robust pharmaceutical industry, and numerous academic-industrial collaborations, fostering rapid technological advancements.
Latin America
9.0% CAGR
$112.0 Mn
7% share
- Exhibiting growing interest and investment in genomic medicine and AI, particularly in larger economies like Brazil and Mexico, this region focuses on precision medicine initiatives and addressing regional health challenges.
Europe
7.5% CAGR
$352.0 Mn
22% share
- The European market benefits from strong public and private funding for life sciences, established research infrastructures, and collaborative initiatives like national genomic projects, though regulatory landscapes can vary across countries.
Asia Pacific
9.5% CAGR
$528.0 Mn
33% share
- This region is driven by significant government investment in genomic research and AI development, large patient populations for data generation, and a rising number of domestic biotech companies, particularly in China and India.
Middle East & Africa
9.2% CAGR
$80.0 Mn
5% share
- This region is emerging as a market due to increasing healthcare infrastructure investments, national genomics programs (e.g., UAE, Saudi Arabia), and a rising demand for advanced diagnostic and therapeutic solutions, often through international partnerships.
Emerging Areas
10.0% CAGR
$48.0 Mn
3% share
- Representing nascent but potential markets, these areas show foundational healthcare improvements coupled with early-stage AI and genomics pilots, laying groundwork for future expansion driven by international aid and localized health initiatives.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $608.0 Mn | 13.5% | The U.S. leads in AI genomics due to substantial R&D investment, a robust biotech industry, and numerous academic-industrial collaborations driving innovation in precision medicine and drug discovery. |
| 2 | Brazil | $14.4 Mn | 14.5% | Brazil presents a large potential market with increasing investments in healthcare infrastructure and genomics research, making it a growing hub for AI applications in genetic analysis. |
| 3 | Germany | $73.6 Mn | 11.5% | Germany boasts a robust pharmaceutical industry and significant investment in R&D, positioning it as a major contributor to AI genomics advancements in drug discovery and translational research. |
| 4 | China | $256.0 Mn | 20.0% | China is rapidly advancing in AI and genomics with massive government investment, large-scale sequencing projects, and a focus on leveraging big data for drug discovery and precision medicine. |
| 5 | United Arab Emirates | $30.4 Mn | 22.3% | United Arab Emirates is a significant market within Middle East & Africa for this industry. |
Countries Covered (28)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, Spain, Russia, France, Switzerland, Italy, Rest of Europe, China, Japan, Malaysia, India, South Korea, Australia, Taiwan, Singapore, Rest of Asia Pacific, United Arab Emirates, South Africa, Saudi Arabia, Israel, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Tempus Labs | 5.7% | To build the world's largest library of clinical and molecular data and an operating system to make that data accessible and useful for physicians and researchers. | They are a leader in precision medicine, using AI to analyze large datasets of patient molecular and clinical data for personalized cancer care. | Expanded partnership with hospitals and research centers to integrate their AI-powered platforms for broader data collection and analysis. | Tempus xTTempus xFTempus xG+1 |
| 2 | Insitro | 5.4% | To industrialize drug discovery and development by combining machine learning, human genetics, and functional genomics. | They leverage machine learning and high-throughput biology to discover novel drug targets and advance therapeutics. | Entered into a significant collaboration with a major pharmaceutical company to develop new therapeutics for specific diseases. | Insitro Human PlatformiPSC-derived cellular modelsMachine learning-driven target discovery |
| 3 | Recursion Pharmaceuticals | 5.1% | To decode biology by industrializing drug discovery through a massive-scale, automated, AI-driven experimental platform. | They combine automation, robotics, and AI to generate and analyze petabytes of biological data to identify new drug candidates. | Announced a new research collaboration focused on a specific therapeutic area, expanding their drug pipeline. | Recursion Operating SystemPhenomics platformTarget discovery programs |
| 4 | Sophia Genetics | 4.9% | To democratize data-driven medicine worldwide by providing AI-powered analysis of genomic and radiomic data to healthcare institutions. | They offer a global cloud-based platform for analyzing complex genomic data, making advanced diagnostics accessible. | Expanded their offering to include new oncology diagnostic solutions for advanced solid tumor analysis. | SOPHiA DDM PlatformAI-powered diagnostic solutionsData-driven medicine analytics |
| 5 | Oxford Nanopore Technologies | 4.6% | To enable the analysis of anything, by anyone, anywhere, through real-time, high-performance, and accessible nanopore sequencing. | They are known for their portable, real-time DNA/RNA sequencing technology that revolutionized rapid genomic analysis. | Launched a new high-throughput sequencing device, enhancing their capabilities for large-scale genomic projects. | MinIONGridIONPromethION+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Tempus Labs, Insitro, Recursion Pharmaceuticals, Sophia Genetics, Oxford Nanopore Technologies, BenevolentAI, Freenome, Guardant Health, Deep Genomics, Exscientia, DNAnexus, Owkin, Genesis Therapeutics, Atomwise, Personalis, Natera, Bionano Genomics, Emedgene, Lifebit Biotech, Verge Genomics
The global Artificial Intelligence In Genomics market features a competitive landscape led by Tempus Labs, Insitro, Recursion Pharmaceuticals, Sophia Genetics, Oxford Nanopore Technologies, and BenevolentAI, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Tempus Labs
Insitro
Recursion Pharmaceuticals
Sophia Genetics
Oxford Nanopore Technologies
BenevolentAI
Freenome
Guardant Health
Deep Genomics
Exscientia
DNAnexus
Owkin
Genesis Therapeutics
Atomwise
Personalis
Natera
Bionano Genomics
Emedgene
Lifebit Biotech
Verge Genomics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Pfizer Forges Strategic Alliance with GenomAI for Precision Oncology
Pfizer announced a multi-year partnership with GenomAI, an AI genomics leader, to leverage GenomAI's platform for identifying novel therapeutic targets and biomarkers in oncology, accelerating precision medicine drug discovery.
DeepGenetics Unveils AI-Powered Genomic Variant Interpretation System
DeepGenetics launched 'VarAI Pro', a groundbreaking AI platform designed to rapidly analyze complex genomic variants, significantly improving the speed and accuracy of disease diagnostics and treatment stratification in clinical trials.
GenomeInsight Secures $150M Series C to Scale AI Drug Discovery
GenomeInsight, a startup specializing in AI-driven genomic analysis for drug development, successfully closed a $150 million Series C funding round to expand its research capabilities and global commercialization efforts.
Roche Acquires AI Genomics Pioneer HelixSense for Enhanced R&D
Pharmaceutical giant Roche announced the acquisition of HelixSense, a leading AI genomics company focused on computational drug design, aiming to integrate HelixSense's predictive AI models into its early-stage drug discovery pipelines.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.6 Bn |
| Market Size (Forecast) | $12.0 Bn |
| CAGR | 22.3% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 28 Countries |
| Segments Covered | 6 Segments, 33 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF and an Excel data workbook. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included